Quantum BioPharma Advances Neurological Pipeline and Consumer Wellness Product

Neurological disorders have become a leading global health challenge, affecting over one-third of the world's population, according to the World Health Organization. Current therapies often focus on symptom management rather than halting disease progression, creating a pressing need for new approaches. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is responding to this demand by advancing a diversified pipeline that spans both neurological therapies and consumer wellness products.

Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma is developing LUCID-MS, a patented new chemical entity aimed at addressing an unmet need in multiple sclerosis (MS). Unlike existing MS drugs that primarily manage symptoms, LUCID-MS targets the underlying neurodegeneration, potentially preserving mobility and function—a critical gap in current treatment options. The company's focus on neuroprotection aligns with industry-wide efforts to shift from symptom control to disease modification.

Beyond pharmaceuticals, Quantum BioPharma has expanded into the consumer market with unbuzzd, an innovative, clinically validated alcohol metabolism accelerator designed to help individuals sober up faster. This product targets the growing demand for health-conscious solutions related to alcohol consumption, offering a novel approach to mitigating alcohol's effects. The company's involvement in both prescription drugs and over-the-counter wellness products reflects a strategy to address broad healthcare needs while leveraging its research capabilities.

The company's newsroom at https://ibn.fm/QNTM provides updates on these developments. Investors should note the forward-looking statements and associated risks detailed in the company's SEC filings, including its Annual Report on Form 10-K and quarterly reports on Form 10-Q, as discussed in the disclaimer at http://IBN.fm/Disclaimer.

Quantum BioPharma's dual focus on neurological disease and consumer wellness positions it at the intersection of two high-growth markets. As the burden of neurological conditions continues to rise, the success of LUCID-MS could provide a meaningful treatment option for MS patients. Simultaneously, unbuzzd addresses a widespread consumer need, potentially capturing a significant share of the alcohol health market. The company's ability to advance both pipelines will depend on clinical outcomes and regulatory approvals, but its diversified approach mitigates single-product risk.

The implications of this announcement are significant for patients and investors alike. For those affected by MS, LUCID-MS offers hope for a therapy that targets the root cause of disease progression rather than just symptoms. For consumers, unbuzzd presents a novel solution to alcohol metabolism, which could have broad public health benefits. As Quantum BioPharma continues to develop these assets, its progress will be closely watched by the medical community and market participants.